EP Patent

EP2845596A3 — Use of lipid conjugates in the treatment of disease

Assigned to Yissum Research Development Co of Hebrew University of Jerusalem · Expires 2015-07-15 · 11y expired

What this patent protects

A phospholipid conjugate according to the general formula (I) or according to the general formula (II) for use in the treatment or prevention of a disorder selected from skin hypersensitivity, respiratory disease, eye disorder, and inflammatory bowel disease.

USPTO Abstract

A phospholipid conjugate according to the general formula (I) or according to the general formula (II) for use in the treatment or prevention of a disorder selected from skin hypersensitivity, respiratory disease, eye disorder, and inflammatory bowel disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP2845596A3
Jurisdiction
EP
Classification
—
Expires
2015-07-15
Drug substance claim
No
Drug product claim
No
Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.